Trump plans to oust FDA commissioner Marty Makary: what is reported, what is not final, and why it matters

What is being reported—and how certain it is

By May 8, 2026, major news organizations were publishing conflicting levels of certainty about the same headline: that President Donald Trump intends to remove Dr. Marty Makary as Food and Drug Administration (FDA) commissioner. NBC News, citing one source familiar with the matter, said Trump was “considering” firing Makary and had not made a final decision, adding that the president “could always change his mind.”

STAT, summarizing The Wall Street Journal, Bloomberg, and Politico, said Trump had reportedly signed off on a plan to dismiss Makary while noting that plans could still change—a common caveat in sourced West Wing stories where paperwork, timing, and last-minute calls can alter outcomes. Treat this as a developing personnel story: the directional signal is serious, but until the White House issues a termination letter or a public announcement, outsiders are inferring intent from leaks and pressure campaigns rather than from a posted order.

Who Makary is and how he got the job

Makary is a surgeon and public-health commentator who was closely associated with “Make America Healthy Again” messaging and was widely described as aligned with Health and Human Services Secretary Robert F. Kennedy Jr. He was confirmed as FDA commissioner in March 2025, meaning a May 2026 exit would end a tenure of roughly 14 months—long enough to set policy direction but short by historical FDA standards.

During that window, Makary’s FDA advanced high-visibility initiatives that matched the administration’s food-and-drug themes—including tighter scrutiny of some vaccine pathways and efforts to reduce artificial dyes in the food supply—while also becoming a magnet for industry and Capitol Hill criticism over unpredictable regulatory decisions.

The friction points reporters keep naming

Coverage converges on a handful of recurring stress tests. First, mifepristone: Makary told senators during confirmation he would pursue a safety review of the abortion pill, but NBC News noted that more than a year later no review had been released, intensifying pressure from anti-abortion advocates who want stricter dispensing rules while abortion-rights groups watch for restrictions. Bloomberg had previously reported agency officials were told to delay release until after midterms—a detail that, if accurate, illustrates how electoral politics can hover over drug-safety communications.

Second, rare-disease and biotech decisions: the FDA under Makary drew fire for rejecting or refusing to review high-stakes applications—NBC cited a Huntington’s disease gene therapy episode that sparked outrage and contributed to leadership turbulence in the relevant office, alongside an mRNA flu vaccine filing that saw a quick reversal after initial resistance. Third, nicotine policy: NBC and STAT tied Trump’s frustration to flavored vaping products, linking it to campaign promises to “save” vaping and to reporting that Trump wanted faster movement on flavored nicotine approvals—tension that collides with pediatric public-health concerns about youth use.

Why FDA churn ripples beyond one appointee

The FDA sits at the intersection of public health, national security (blood supply, outbreak response), and industrial competitiveness (biotech approvals). Commissioner turnover does not automatically invalidate scientific staff work, but it can delay guidance, reorganize centers, and shift review culture—especially when political principals disagree about risk tolerance.

STAT noted broader vacancy pressure across HHS, including leadership gaps at other Senate-confirmed posts, and observed that key FDA divisions already lacked permanent heads. A forced commissioner exit would add search cost and uncertainty for companies awaiting PDUFA dates, inspection cadence, and enforcement priorities—even if an acting commissioner maintains statutory functions.

What official Washington said on the record

In NBC’s piece, White House spokesman Kush Desai offered a generic defense of the administration’s staffing: “President Trump has assembled the most experienced and talented administration in history…” without confirming or denying Makary’s status. That kind of non-denial is typical when a personnel story is live but not yet packaged for announcement.

STAT said the White House and spokespeople for Makary and Kennedy did not answer its messages—also common in fast-moving exits. Reporters also noted Makary’s public demeanor remained upbeat at a conference encounter—“Feeling good,” with a thumbs-up—which can reflect genuine confidence, spin, or both.

Bottom line

Sourced reporting on May 8, 2026 describes President Trump moving toward removing FDA Commissioner Marty Makary, with NBC emphasizing a non-final decision and other outlets describing a plan signed off subject to last-minute change. The substantive through-line is political frustration with an agency perceived as slow or obstructive on priority files—from abortion-pill politics to nicotine flavors—layered atop controversial biotech calls and morale problems.

Readers should watch for three concrete signals next: a formal White House statement, an acting commissioner designation, and any Senate timing for a permanent nominee—because until those appear, the story remains probable personnel change, not settled fact.